Manufacturing an Enhanced CAR T Cell Product By Inhibition of the PI3K/Akt Pathway During T Cell Expansion Results in Improved In Vivo Efficacy of Anti-BCMA CAR T Cells

癌症研究 嵌合抗原受体 淋巴瘤 CD19 细胞培养 T细胞 CD28 离体 PI3K/AKT/mTOR通路 免疫学 体内 抗原 医学 生物 细胞生物学 信号转导 免疫系统 遗传学 生物技术
作者
Molly R. Perkins,Shannon M. Grande,Amanda Hamel,Holly M. Horton,Tracy E. Garrett,Sara M. Miller,Howard J. Latimer,Christopher J. Horvath,Michael Kuczewski,Kevin M. Friedman,Richard A. Morgan
出处
期刊:Blood [Elsevier BV]
卷期号:126 (23): 1893-1893 被引量:27
标识
DOI:10.1182/blood.v126.23.1893.1893
摘要

Abstract Patients treated with chimeric antigen receptor (CAR) T cells targeting CD19 for B cell malignancies have experienced rapid and durable tumor regressions. Manufacture of CAR T cells is challenged by the necessity to produce a unique drug product for each patient. Each treatment requires ex vivo culture of patient T cells to facilitate CAR gene transfer and to achieve therapeutic amounts of T cells. Paradoxically, ex vivo culture with IL-2 also decreases CAR T cell activity. Some investigators have proposed isolating central memory T cells (thought to be enriched for therapeutic T cells), yet isolation techniques are cumbersome and costly to scale commercially. Culture of T cells in IL-7 and IL-15 has also been shown by several investigators to improve therapeutic activity. Here we explored the potential for culture modifications to improve the therapeutic potential of CAR T cells without adding complexity to manufacturing. We tested this hypothesis using CAR T cells specific to B cell maturation antigen (BCMA) manufactured using standard IL-2 culture with an inhibitor of PI3K added to the media, or with IL-7 and IL-15 in place of IL-2. The in vivo activity was studied in NSG mouse models of human Burkitt's lymphoma (Daudi), and multiple myeloma (RPMI-8226), both of which express BCMA. In the lymphoma model, NSG mice were injected intravenously (IV) with 2 x 106 Daudi cells and allowed to accumulate a large tumor burden before being treated with 4 x 106 CAR+ T cells on day 18 post-tumor injection. At this late time point post implantation, mice had highly disseminated Daudi tumor (our goal was to model late stage disease observed in relapsed and refractory lymphoma). In this model of advanced disease, IL-2 cultured anti-BCMA CAR T cells had no effect on tumor growth (p = 0.22) and all mice succumbed to the tumors within two weeks after treatment. Anti-BCMA CAR T cells grown in IL-7 and IL-15 also failed to control tumor growth (p = 0.23). In sharp contrast, all animals treated with anti-BCMA CAR T cells cultured with the PI3K inhibitor survived and experienced complete long-term tumor regression (p=0.003). The same anti-BCMA CAR T cells were used in a model of multiple myeloma. NSG mice were injected subcutaneously (SC) with 107 RPMI-8226 MM cells, and at 22 days post-implantation mice received a single IV administration of anti-BCMA CAR T cells (4 x 105 CAR+ T cells/mouse) cultured under various conditions. In this model, all treatment groups demonstrated tumor regression, regardless of the in vitro culture conditions. To evaluate CAR T cell durability, two weeks after initial tumor clearance, surviving animals were then re-challenged with RPMI-8226 cells on the opposite flank to model tumor relapse. We found that only animals that had been treated with anti-BCMA CAR T cells cultured with PI3K inhibition were immune to subsequent tumor challenge (p=0.005). Given the superior in vivo efficacy of anti-BCMA CAR T cells cultured with PI3K inhibition, we sought to identify phenotypic characteristics associated with the improved therapeutic activity. Anti-BCMA CAR T cells cultured with PI3K inhibition contained an increased frequency of CD62L+ CD8 T cells in the final product (p < 0.001) suggesting improved expansion of a distinct CD8 T cell subset. These data suggest that inhibition of PI3K during ex vivo expansion with IL-2 may generate a superior anti-BCMA CAR T cell product for clinical use. Furthermore, this approach could potentially be used in the manufacture of other T cell therapies. Disclosures Perkins: bluebird bio: Employment, Equity Ownership. Grande:bluebird bio: Employment, Equity Ownership. Hamel:bluebird bio: Employment, Equity Ownership. Horton:bluebird bio: Employment, Equity Ownership. Garrett:bluebird bio: Employment, Equity Ownership. Miller:bluebird bio: Employment, Equity Ownership. Latimer:bluebird bio: Employment, Equity Ownership. Horvath:bluebird bio: Employment, Equity Ownership. Kuczewski:bluebird bio: Employment, Equity Ownership. Friedman:bluebird bio: Employment, Equity Ownership. Morgan:bluebird bio: Employment, Equity Ownership.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
今后的应助被Hou采纳,获得10
刚刚
yy发布了新的文献求助10
刚刚
CodeCraft的应助被SUN采纳,获得10
刚刚
乐乐的应助被houyushen采纳,获得10
1秒前
1秒前
1秒前
所所的应助被李小昌采纳,获得10
1秒前
1秒前
Owen的应助被山水采纳,获得10
1秒前
1秒前
cdercder的应助被成一采纳,获得10
1秒前
qqhappy完成签到,获得积分10
2秒前
玊尔玉发布了新的文献求助10
2秒前
zhancon完成签到,获得积分10
2秒前
imfangyu完成签到,获得积分10
2秒前
洁净龙猫完成签到,获得积分20
2秒前
瀛洲晚风发布了新的文献求助10
2秒前
3秒前
3秒前
CarryLJR发布了新的文献求助30
3秒前
3秒前
4秒前
4秒前
华仔的应助被能干千凡采纳,获得10
4秒前
ymy发布了新的文献求助10
4秒前
红茸茸羊发布了新的文献求助10
5秒前
Hang完成签到,获得积分10
5秒前
Ava的应助被coco采纳,获得10
5秒前
昵称太土完成签到,获得积分10
5秒前
wang完成签到,获得积分10
5秒前
5秒前
6秒前
刘思琪发布了新的文献求助10
7秒前
予光完成签到,获得积分10
7秒前
7秒前
傲娇的之玉完成签到,获得积分10
7秒前
wencc发布了新的文献求助10
7秒前
rrrryym完成签到,获得积分10
7秒前
7秒前
高高的城发布了新的文献求助10
7秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
Resource Recovery Handbook 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8175695
求助须知:如何正确求助?哪些是违规求助? 9567289
关于积分的说明 21792006
捐赠科研通 7770255
什么是DOI,文献DOI怎么找? 3431873
关于科研通互助平台的介绍 2556250
邀请新用户注册赠送积分活动 2477335